Imlunestrant

Published

dm+d

Unassigned

New Medicines

ER-positive HER2-negative metastatic breast cancer

Information

New molecular entity
Eli Lilly
Eli Lilly

Development and Regulatory status

None
Phase III Clinical Trials
Phase III Clinical Trials

Category

A selective estrogen receptor degrader (SERD)
In 2017 in England, 46,109 people were diagnosed with BC. Approx. 13% have advanced disease when they are diagnosed, and ~35% of people with early or locally advanced disease will progress to metastatic BC in the 10 years following diagnosis. Most (80%) BCs are hormone-receptor positive and two‐thirds are oestrogen receptor positive. Human epidermal growth factor receptor 2 (HER2) is present in ~15-25% of BC. Approx. 64% of women with metastatic BC have HR-positive, HER2-negative disease [1].
ER-positive HER2-negative metastatic breast cancer
Oral